Heidelberg Pharma AG announces pre‑clinical results of its ADC platform at AACR 2026
Heidelberg Pharma AG (ticker: HPHA) reported that it will present promising pre‑clinical data from its Amanitin‑based antibody‑drug conjugate (ADC) HDP‑103 at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California, from 17 to 22 April.
The company’s press release, issued from Ladenburg on 4 April 2026, details that HDP‑103 is designed to target metastatic castration‑resistant prostate cancer (mCRPC). The ADC employs a prostate‑specific membrane antigen (PSMA) targeting moiety and delivers the potent cytotoxin amanitin to tumour cells. Early animal studies, as presented in the poster titled “HDP‑103, a PSMA‑targeting amanitin‑based ADC, is efficacious even in difficult‑to‑treat patient‑derived xenograft models with heterogeneous PSMA expression,” showed significant tumour growth inhibition in pre‑clinical models that are typically refractory to existing therapies.
Heidelberg Pharma’s focus on ADC technology aligns with its broader strategy of developing novel oncology therapies. The company has been conducting research in pharmacology, drug metabolism, pharmacokinetics, and molecular biology targeting both oncology and inflammatory diseases. By showcasing HDP‑103 at AACR 2026, Heidelberg Pharma aims to strengthen its scientific credibility and potentially attract further collaboration or investment opportunities.
The presentation is part of a series of scientific disclosures by Heidelberg Pharma, which is listed on the Xetra stock exchange under the ticker HPHA. The company’s market capitalization stands at approximately €138.95 million, and its stock price closed at €2.97 on 1 April 2026. The firm’s 52‑week high and low were €5.36 and €2.20, respectively, recorded on 5 June 2025 and 6 April 2025.
Heidelberg Pharma’s public offering took place on 13 November 2006, and it continues to serve patients and healthcare professionals in Germany with a focus on innovative biopharmaceutical solutions. For further information, the company’s website is www.heidelberg-pharma.com .
